Improving CAR T cell therapy for solid tumors
Official title: Tuning KITv CAR T cells for the solid tumor environment
Funded at Sloan-Kettering Inst Can Research · NIH-10943749 · Data updated 2026-11-12
This study is testing a new type of CAR T cell therapy designed to help patients with malignant pleural mesothelioma by targeting a specific protein found in many tumors, with the hope of making the treatment more effective and safer for those who have already had other treatments.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Sloan-Kettering Inst Can Research NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | August 13, 2024 |
| Project end | July 31, 2029 |
| Funding year | 2024 |
| Award (this year) | $655,042 |
| NIH project number | 1R01CA292664-01 |
| Project ID | NIH-10943749 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with malignant pleural mesothelioma or other solid tumors that express mesothelin.
✕Less likely to help
Patients with solid tumors that do not express mesothelin or those with other types of cancer may not benefit from this research.
What this research studies
This research focuses on enhancing CAR T cell therapy by developing a new type of CAR T cell that targets a specific cancer-associated antigen called mesothelin, which is found in many solid tumors. The approach involves administering these modified T cells directly into the pleural space of patients with malignant pleural mesothelioma, aiming to improve their ability to infiltrate tumors and resist suppression by the tumor environment. The study also explores the use of a novel receptor to enhance the effectiveness of the therapy while minimizing side effects. Patients who have previously received treatment will be monitored for safety and effectiveness, with the goal of improving survival rates.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for patients with solid tumors, potentially improving survival rates and reducing side effects.
How similar studies have gone: Previous studies have shown promising results with similar CAR T cell therapies targeting solid tumors, indicating potential for success in this novel approach.
Where this research is happening
-
Sloan-Kettering Inst Can Research
New York, United States Active
Researchers
- Principal investigator: Adusumilli, Prasad S. — Sloan-Kettering Inst Can Research
- Study coordinator: Adusumilli, Prasad S.
Related research
Other NIH-funded projects on the same topics.
-
Dual-targeted DOTA CAR T cells with image-guided monitoring for solid tumors
A Penn team is developing a controllable CAR T cell therapy for solid tumors that can be tracked with PET imaging and guided by targeted agents to improve safety and effectiveness.
-
Improving patient access to gynecologic cancer trials at UVA
This grant helps UVA boost enrollment in gynecologic and solid tumor trials so more women with gynecologic cancers can access cutting-edge therapies.
-
Tuning CAR T cells to work better in solid tumors
A cancer-immunotherapy approach uses specially trained CAR T cells designed to attack solid tumors more effectively and safely.
-
A 3D lab tool to see how solid tumors squeeze and spread
This project builds a tiny 3D device that measures how solid tumors push, deform, and let cancer cells break away, which could help people with cancers that form solid tumors.
-
Dual-target CAR T therapy with PET tracking for solid tumors
A controllable CAR T-cell treatment that doctors can track with PET scans and direct at solid tumors in adults whose cancers express folate receptors.
-
Atlas of the tumor environment in childhood cancers
This project will map the cells and signals surrounding childhood solid tumors like neuroblastoma, rhabdomyosarcoma, and Wilms tumor to find weaknesses that could help children with high-risk disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.